Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02518958
Title A Phase I, Open-Label, Multiple Ascending Dose Study of RRx-001 and Nivolumab
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors EpicentRx, Inc.
Indications

Advanced Solid Tumor

lymphoma

Therapies

Nivolumab

Age Groups: adult
Covered Countries USA


No variant requirements are available.